• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

Polar Capital Biotechnology I GBP

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider Polar
Fund Summary The objective of the Fund is to preserve capital and achieve long term capital appreciation by investing worldwide in the shares of biotechnology, diagnostics and life sciences tools companies.
SEDOL code B42P0H7
ISIN IE00B42P0H75
Fund code POBII
Managers David Pinniger
Manager Tenure 6 years
Morningstar Category Sector Equity Biotechnology
IMA Sector Specialist
Fund Size £431 million
Fund Type OEIC
Management Style Active
Total Expense Ratio (TER) 1.23%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £19.73
Buy Price £19.73
Price Change +0.5094%
Price Date 18th July 2019
Yield Currently unavailable
Dividend Frequency Yearly
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 31st October 2013
Fund Status OPEN
David joined Polar Capital in August 2013 as a Fund Manager within the healthcare team. He has over 14 years investment experience in the healthcare sector. Prior to joining Polar Capital, for five years David was Portfolio Manager of the International Biotechnology Trust at SV Life Sciences

3-year Mean Monthly Return: 1.619%

Annual Returns 2018 2017 2016 2015 2014
Fund Performance +4.91% +18.39% +37.37% -9.67% +59.34%
Benchmark Performance
(Sector Equity Biotechnology)
-5.14% +9.22% +23.07% -15.73% +40.05%
Time Period Cumulative Benchmark Performance
(Sector Equity Biotechnology)
Fund Compared to Benchmark
1 day 0.82% -0.48% +1.30%
1 week -0.10% -0.45% +0.34%
1 month 5.54% +0.44% +5.10%
3 months 3.48% -5.05% +8.53%
6 months 6.34% +0.12% +6.22%
1 year 0.87% -2.15% +3.03%
3 years 62.42% +31.77% +30.65%
5 years 160.21% +65.47% +94.74%
10 years Currently unavailable +372.96% Currently unavailable
YTD 17.70% +10.66% +7.03%
Since inception 214.93% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
Alexion Pharmaceuticals Inc USA 6.98%
Incyte Corp USA 6.25%
Vertex Pharmaceuticals Inc USA 5.85%
argenx SE LUX 5.59%
Regeneron Pharmaceuticals Inc USA 4.86%
Sage Therapeutics Inc USA 4.32%
NanoString Technologies Inc USA 4.29%
Evotec SE DEU 3.88%
MyoKardia Inc USA 3.75%
Stemline Therapeutics Inc USA 3.30%

Currently unavailable